Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has been launched in South Korea. Leqembi received the Ministry ...

The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

Our analysis of options history for Biogen BIIB revealed 12 unusual trades. Delving into the details, we found 25% of traders ...

The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.

"Samsung Biologics inks $668m manufacturing deal with European pharma " was originally created and published by ...

Happenings in Boston’s life sciences ecosystem this past week include the departure of a general partner from Apple Tree Partners for another firm, Kronos Bio seeks "strategic alternatives" and new ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

Today, Benzinga 's options scanner spotted 9 uncommon options trades for Biogen. This isn't normal. The overall sentiment of ...